The University of Florida’s Pepper, the pet cat who made headlines last year for discovering the first jeilongvirus found in the U.S., has done it again. This time, his keen senses have led researchers to a new strain of orthoreovirus, which is known to infect humans, white-tailed deer, bats, and other mammals.

John Lednicky, Ph.D., Pepper’s owner and a University of Florida College of Public Health and Health Professions virologist, was testing a specimen from an Everglades short-tailed shrew when he stumbled upon the new virus. The discovery came as part of his ongoing work to understand transmission of the mule deerpox virus.

Lednicky’s team published the complete genomic coding sequences for the virus they named “Gainesville shrew mammalian orthoreovirus type 3 strain UF-1” in the journal Microbiology Resource Announcements. The researchers note that while there have been rare reports of orthoreoviruses being associated with cases of encephalitis, meningitis, and gastroenteritis in children, more research is needed to understand their effects on humans.

“We need to pay attention to orthoreoviruses and know how to rapidly detect them,” Lednicky said. “There are many different mammalian orthoreoviruses, and not enough is known about this recently identified virus to be concerned.”

Pepper’s contributions to scientific discovery continue unabated. His specimen collection has led researchers to the identification of two other novel viruses found in farmed white-tailed deer, highlighting the importance of continued research into the ever-evolving world of viruses.

The discovery of new viruses is not surprising, given their propensity to constantly evolve and the sophisticated lab techniques used by researchers like Lednicky. “If you look, you’ll find,” he said. “And that’s why we keep finding all these new viruses.”

Lednicky and his team plan to conduct further research into the new virus, including serology and immunology studies to understand its potential threat to humans, wildlife, and pets.

Meanwhile, Pepper remains healthy and continues to contribute to scientific discovery through his outdoor adventures. As Lednicky said, “If you come across a dead animal, why not test it instead of just burying it? There is a lot of information that can be gained.”

Cancer cells have a notorious ability to multiply rapidly and spread easily throughout the body. One of the reasons they are so successful is their ability to undergo a process called epithelial-to-mesenchymal plasticity, which makes them resistant to elimination by anticancer therapies. In an effort to find new ways to combat this resistance, researchers have been searching for newer anticancer agents that can target these “rogue” cancer cells.

A team of scientists led by Dr. Hideyuki Saya, Director of the Oncology Innovation Center at Fujita Health University in Japan, has made a groundbreaking discovery about the potential of benzaldehyde to halt therapy-resistant pancreatic cancer. This sweet-smelling molecule is responsible for the aroma of almonds, apricots, and figs, but it also has potent anticancer properties.

The researchers were driven by a desire to uncover the mechanism behind benzaldehyde’s anticancer effects, particularly after learning that one of their colleagues had demonstrated its potential back in the 1980s. The first author of the study, Dr. Jun Saito, was motivated by her parents’ pioneering work on benzaldehyde and its derivatives.

The team conducted extensive research using a mouse model grafted with growing pancreatic cancer cells. They found that benzaldehyde inhibited the growth of these cancer cells, even when they had become resistant to radiation therapy and treatment with osimertinib, an agent blocking tyrosine kinases in growth factor signaling.

Their findings revealed that benzaldehyde exerts its anticancer effects by preventing interactions between a key signaling protein called 14-3-3ζ and histone H3. This interaction is crucial for cancer cell survival and treatment resistance. By blocking this interaction, benzaldehyde reduced the expression of genes related to epithelial-mesenchymal plasticity.

The study also showed that benzaldehyde synergized with radiation therapy to eliminate previously resistant cancer cells. Furthermore, a derivative of benzaldehyde was found to inhibit the growth of pancreatic tumors and suppress epithelial-to-mesenchymal plasticity, preventing metastasis.

Dr. Saya’s team believes that their results suggest that inhibition of the interaction between 14-3-3ζ and its client proteins by benzaldehyde has the potential to overcome the problem of therapy resistance. This study opens up possibilities for using benzaldehyde as a combinatorial anticancer agent, alongside molecular-targeted therapies.

The implications of this research are significant, offering new hope for patients with therapy-resistant pancreatic cancer. Further studies will be necessary to confirm these findings and explore their potential applications in the clinic.

The discovery of an “off switch” enzyme that can help prevent heart disease and diabetes is a significant breakthrough in the medical field. Scientists at The University of Texas at Arlington have identified an enzyme called IDO1, which plays a crucial role in inflammation regulation. By blocking this enzyme, researchers believe they can control inflammation and restore proper cholesterol processing.

Inflammation is a natural response to stress, injury, or infection, but when it becomes abnormal, it can lead to chronic diseases such as heart disease, cancer, diabetes, and dementia. The team found that IDO1 becomes activated during inflammation, producing a substance called kynurenine that interferes with how macrophages process cholesterol.

When IDO1 is blocked, however, macrophages regain their ability to absorb cholesterol, suggesting a new way to prevent heart disease by keeping cholesterol levels in check. The researchers also discovered that another enzyme linked to inflammation, nitric oxide synthase (NOS), worsens the effects of IDO1.

The findings are crucial because they suggest that understanding how to prevent inflammation-related diseases could lead to new treatments for conditions like heart disease, diabetes, cancer, and others. The research team plans to further investigate the interaction between IDO1 and cholesterol regulation, with the goal of finding a safe way to block this enzyme and develop effective drugs to combat chronic diseases.

The discovery is supported by grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF), indicating the importance of this research in advancing our understanding of inflammation-related diseases. With further study, it’s possible that we may see a new era in disease prevention and treatment, giving hope to millions of people affected by these conditions.